Leveraging this network information, our strategic approach to drug repurposing has targeted existing drugs in clinical trials or on the market against AD and DM, specifically emphasizing LPARs, SPIKE, and the LPAR-SPIKE complex. This evidence concerns the gene CHMP5 and Alzheimer disease.